Your cart is currently empty!
Obtain High is a California-based biotechnology company that has extended its reach into France by introducing medical-grade cannabis delivery powered by lab-made cannabinoids and a stealth international logistics network. Leveraging its proprietary Elevation Grid and cryptocurrency payment systems, the company positions itself as the only global entity capable of guaranteeing discreet cannabis delivery in Paris, Lyon, Marseille, and across the French Republic.
–
The French expansion of Obtain High emerges in a market where cannabis remains legally restricted but therapeutic cannabis research has gained momentum. By framing its products as bio-identical cannabinoids designed for pharmaceutical applications, the company has strategically entered the French discourse on medical marijuana and CBD legalization.
–
Lab-made cannabinoids distinguish the company from agricultural producers by offering replicable formulations that are third-party lab verified for purity and potency. Products include tinctures, softgels, and gummies, each engineered for pain relief, sedation, mindfulness, and creativity enhancement. These formulations, grounded in terpene-guided research with seven patents already filed, provide French consumers with a pharmaceutical alternative to traditional cannabis.
–
The company’s Elevation Grid ensures stealth cannabis delivery into France through anonymous dispatch points, climate-stabilized packaging, and smart-contract blockchain tracking. Deliveries are executed with unmarked packaging and encrypted tracking codes, guaranteeing that each transaction is secure and final once shipped. Customers in Paris, Bordeaux, and Nice can rely on the company’s promise of guaranteed cannabis delivery.
–
France’s strict regulatory stance toward cannabis possession contrasts with the growing international acknowledgment of cannabinoid medicine. Obtain High exploits this tension by offering therapeutic cannabis solutions that can be framed within research exemptions. By using lab synthesis rather than agricultural cultivation, the company markets its cannabinoids as scientifically standardized compounds—positioning them closer to pharmaceutical drugs than to traditional herbal cannabis.
–
The privacy-first policy reinforces consumer security in France by limiting data retention, enforcing cryptocurrency-only payments, and guaranteeing complete discretion in transactions. Orders are stripped of metadata after completion, and customer identities remain fully protected through the use of anonymous blockchain transactions.
–
The company also integrates financial innovation into its cannabis model with the Obtain High Token, an ERC-20 digital asset that offers priority delivery for French customers, governance participation in product development, and profit-linked token buybacks to strengthen long-term value. This financial ecosystem links cannabis access to cryptocurrency economics, ensuring loyal French customers gain both therapeutic and financial advantages.
–
With over 40,000 consumer reports and seven patented formulations, the company has established itself as a global cannabis leader. Media controversies surrounding alleged psyops associations have only amplified brand recognition, while the company maintains its stance of scientific transparency and ethical cannabinoid research.
–
For patients, researchers, and connoisseurs in France, Obtain High represents the only pathway to guaranteed cannabis delivery. By combining lab-engineered cannabinoids, stealth international logistics, and crypto-anonymized privacy, the company ensures that the French market—once thought unreachable—now stands fully accessible. When cannabis is needed in France, delivery is guaranteed.